Center-Authored Papers

Filters: Author is Markman, Maurie  [Clear All Filters]
2015
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
2014
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M.  2014.  Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.. European journal of cancer (Oxford, England : 1990). Abstract
2010
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA.  2010.  Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.. Gynecologic oncology. 119(3):417-21. Abstract
2009
Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu P-Y, Markman M.  2009.  Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.. Gynecologic oncology. 114(2):206-9. Abstract